JNJ supply chain intelligence for Johnson & Johnson: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| PTGX | Protagonist Therapeutics, Inc. | 92% | Reciprocal relationship from PTGX graph: The Company has earned a total of $ 387.5 million in non-refundable payments from JNJ under the JNJ License and Collaboration Agreement |
| GPK | Graphic Packaging Holding Company | 90% | Reciprocal relationship from GPK graph: Health/beauty customers include GlaxoSmithKline, Bayer, Johnson & Johnson, Abbott, Novartis, L’Oréal S.A., Proctor & Gamble, and Colgate. |
| ABBV | AbbVie Inc. | 85% | Reciprocal relationship from ABBV graph: ended March 31, 2026 and $ 242 million for the three months ended March 31, 2025. Sales and marketing and development costs for the three months ended March 3… |
| ANIK | Anika Therapeutics, Inc. | 85% | Reciprocal relationship from ANIK graph: l. The Company had no accrued warranties as of March 31, 2026, or December 31, 2025, and has no history of claims paid. 12 The Company is also involved from t… |
| HBIO | Harvard Bioscience, Inc. | 85% | Reciprocal relationship from HBIO graph: . Army and CROs. Our pharmaceutical and biotechnology customers include pharmaceutical companies and research laboratories such as Abbott, Amgen, AstraZeneca,… |
| PCRX | Pacira BioSciences, Inc. | 85% | Reciprocal relationship from PCRX graph: 025, of which $ million are due in each of 2026 and 2027, $ million in 2028, and $ million in each of 2028 and 2029. The Company has $ million of other minimu… |
| ORGN | Origin Materials, Inc. | 80% | Reciprocal relationship from ORGN graph: HP Embalagens is a major Brazilian packaging company serving world-renowned brands such as Nestlé, Ferrero Rocher, 2 Natura, and Johnson & Johnson. |
| ACIU | AC Immune SA | 72% | Reciprocal relationship from ACIU graph: Reciprocal relationship from JNJ graph: Reciprocal relationship from ACIU graph: Reciprocal relationship from JNJ graph: Reciprocal relationship from ACIU gra… |
| AMIX | Autonomix Medical, Inc. | 72% | Reciprocal relationship from AMIX graph: Reciprocal relationship from JNJ graph: Reciprocal relationship from AMIX graph: Reciprocal relationship from JNJ graph: Reciprocal relationship from AMIX gra… |
| APT | Alpha Pro Tech, Ltd. | 72% | Reciprocal relationship from APT graph: Reciprocal relationship from JNJ graph: Reciprocal relationship from APT graph: Owens Corning and GAF for synthetic roof underlayment. Our major competitor in … |
| BLNK | Blink Charging Co. | 72% | Reciprocal relationship from BLNK graph: . We offer the HQ 200-M Level 2 charger for the mobile/emergency charging market which requires a portable charger to be used for roadside or other use cases … |
| BNR | Burning Rock Biotech Limited | 72% | Reciprocal relationship from BNR graph: days (1) For the year ended December 31, 2024. The design and performance of OncoScreen ™ Plus and OncoCompass ™ Plus has been endorsed by their adoption in ov… |
| CLGN | CollPlant Biotechnologies Ltd. | 72% | Reciprocal relationship from CLGN graph: Reciprocal relationship from JNJ graph: Reciprocal relationship from CLGN graph: funds are secured for its execution. While our upstream and downstream proces… |
| CRSP | CRISPR Therapeutics AG | 72% | Reciprocal relationship from CRSP graph: eline. We believe it has the capacity to support, in whole or in part, the manufacture and supply of product for certain of our current clinical programs with… |
| CVRX | CVRx, Inc. | 72% | Reciprocal relationship from CVRX graph: al device companies that have substantially greater financial, technical, sales and marketing resources than we do, such as Medtronic plc, Boston Scientific C… |
| DYAI | Dyadic International, Inc. | 72% | Reciprocal relationship from DYAI graph: Reciprocal relationship from JNJ graph: Reciprocal relationship from DYAI graph: Reciprocal relationship from JNJ graph: Reciprocal relationship from DYAI gra… |
| ESTA | Establishment Labs Holdings Inc. | 72% | Reciprocal relationship from ESTA graph: Reciprocal relationship from JNJ graph: Reciprocal relationship from ESTA graph: Reciprocal relationship from JNJ graph: Reciprocal relationship from ESTA gra… |
| EVAX | Evaxion A/S | 72% | Reciprocal relationship from EVAX graph: Reciprocal relationship from JNJ graph: Reciprocal relationship from EVAX graph: Reciprocal relationship from JNJ graph: Reciprocal relationship from EVAX gra… |
| EVFM | Evofem Biosciences, Inc. | 72% | Reciprocal relationship from EVFM graph: umber of sales employees; this negatively impacted our ability to maintain our sales and marketing capabilities. Any failure or future delay in the timely dev… |
| GILD | Gilead Sciences, Inc. | 72% | Reciprocal relationship from GILD graph: Reciprocal relationship from JNJ graph: Reciprocal relationship from GILD graph: O Pharma will hold exclusive global rights to STAT6 topical formulations in d… |
| GKOS | Glaukos Corporation | 72% | Reciprocal relationship from GKOS graph: compete with many companies, including divisions of companies much larger than us that may have greater resources and name recognition, and smaller companies … |
| GNLX | Genelux Corporation | 72% | Reciprocal relationship from GNLX graph: d regulatory review of any drug we may develop from our product candidates, it is possible that, before any of our drugs can be commercialized, any related pa… |
| GNMSF | Genmab A/S | 72% | ailability of those raw materials would not likely have a material adverse effect on the financial results of the Company. Patents The Company's subsidiaries have made a practice of obtaining patent … |
| GNMSF | Genmab A/S | 72% | Reciprocal relationship from GNMSF graph: Reciprocal relationship from JNJ graph: ailability of those raw materials would not likely have a material adverse effect on the financial results of the Com… |
| HOLX | Hologic, Inc. | 72% | Reciprocal relationship from HOLX graph: competitors are large imaging companies such as Siemens Healthineers and GE Healthcare, as well as a wide range of medical technology companies that sell a su… |
| IBIO | iBio, Inc. | 72% | Reciprocal relationship from IBIO graph: icantly more experience commercializing drugs that have been approved for marketing. Mergers and acquisitions in the pharmaceutical and biotechnology industri… |
| IMNM | Immunome, Inc. | 72% | Reciprocal relationship from IMNM graph: Reciprocal relationship from JNJ graph: Reciprocal relationship from IMNM graph: m in accordance with the FDA’s good clinical practice, or GCP, requirements, … |
| IMVT | Immunovant, Inc. | 72% | Reciprocal relationship from IMVT graph: Reciprocal relationship from JNJ graph: Reciprocal relationship from IMVT graph: Reciprocal relationship from JNJ graph: Reciprocal relationship from IMVT gra… |
| IVF | INVO Fertility, Inc. | 72% | Reciprocal relationship from IVF graph: ls for our product candidates may be larger than it anticipates, enrollment in these clinical trials may be slower than it anticipate or may be lower than it a… |
| JANX | Janux Therapeutics, Inc. | 72% | Reciprocal relationship from JANX graph: ach master cell bank is or will be stored in two independent locations, and we intend to produce working cell banks for each product candidate later in the co… |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| USGOV-DEPARTMENT-OF-DEFENSE | USGOV-DEPARTMENT-OF-DEFENSE | 95% | USAspending awards from Department of Defense: $4,319,296 across 9 awards. SPE2D625F1LZG 4569174801!2.7MM/3.5MM VA-LCP ANKLE; SPE2D625F2EMD 4569301060!2.7MM/3.5MM VA-LCP ELBOW; SPE2D625F13XT 45668464… |
| TMCI | Treace Medical Concepts, Inc. | 80% | Reciprocal relationship from TMCI graph: Reciprocal relationship from JNJ graph: Reciprocal relationship from TMCI graph: Reciprocal relationship from JNJ graph: Reciprocal relationship from TMCI gra… |
| ACIU | AC Immune SA | 72% | Reciprocal relationship from ACIU graph: ave achieved and our goal of a close working relationship with the regulatory agencies, in particular the FDA and the EMA, are intended to facilitate expediti… |
| AMIX | Autonomix Medical, Inc. | 72% | Reciprocal relationship from AMIX graph: Reciprocal relationship from JNJ graph: Reciprocal relationship from AMIX graph: a limited number of regions or Key Opinion Leaders ("KOLs") to refine and opt… |
| APT | Alpha Pro Tech, Ltd. | 72% | Reciprocal relationship from APT graph: Reciprocal relationship from JNJ graph: Reciprocal relationship from APT graph: We manufacture, cut, warehouse and ship disposable protective apparel products … |
| CLGN | CollPlant Biotechnologies Ltd. | 72% | Reciprocal relationship from CLGN graph: funds are secured for its execution. While our upstream and downstream processes are quite robust and efficient, we continuously invest in further yield impro… |
| CRSP | CRISPR Therapeutics AG | 72% | Reciprocal relationship from CRSP graph: Reciprocal relationship from JNJ graph: Reciprocal relationship from CRSP graph: Reciprocal relationship from JNJ graph: Reciprocal relationship from CRSP gra… |
| CVRX | CVRx, Inc. | 72% | Reciprocal relationship from CVRX graph: al device companies that have substantially greater financial, technical, sales and marketing resources than we do, such as Medtronic plc, Boston Scientific C… |
| CYCN | Cyclerion Therapeutics, Inc. | 72% | Reciprocal relationship from CYCN graph: rovides for the attachment of an additional six months of marketing protection to the term of any existing regulatory exclusivity for both drugs and biologics… |
| ESTA | Establishment Labs Holdings Inc. | 72% | Reciprocal relationship from ESTA graph: Mentor Worldwide LLC (a division of Johnson & Johnson) and Allergan plc (acquired by AbbVie Inc.) have conducted large prospective clinical studies that start… |
| EVAX | Evaxion A/S | 72% | Reciprocal relationship from EVAX graph: ing income in the mid double-digit range. We have initiated a Phase 2 trial, hence this term is no longer relevant. Prior to any out-licensing commercializati… |
| EVFM | Evofem Biosciences, Inc. | 72% | Reciprocal relationship from EVFM graph: Reciprocal relationship from JNJ graph: Reciprocal relationship from EVFM graph: Reciprocal relationship from JNJ graph: Reciprocal relationship from EVFM gra… |
| GLSI | Greenwich LifeSciences, Inc. | 72% | Reciprocal relationship from GLSI graph: Reciprocal relationship from JNJ graph: Reciprocal relationship from GLSI graph: Reciprocal relationship from JNJ graph: Reciprocal relationship from GLSI gra… |
| GNLX | Genelux Corporation | 72% | Reciprocal relationship from GNLX graph: Reciprocal relationship from JNJ graph: Reciprocal relationship from GNLX graph: d regulatory review of any drug we may develop from our product candidates, i… |
| GNMSF | Genmab A/S | 72% | Reciprocal relationship from GNMSF graph: Reciprocal relationship from JNJ graph: Reciprocal relationship from GNMSF graph: Reciprocal relationship from JNJ graph: Reciprocal relationship from GNMSF … |
| GNMSF | Genmab A/S | 72% | Item 8 of this Report. Sales of the Company’s largest product, collectively DARZALEX (daratumumab) and DARZALEX FASPRO (daratumumab and hyaluronidase-fihj), accounted for approximately 15.0% of the C… |
| HBIO | Harvard Bioscience, Inc. | 72% | Reciprocal relationship from HBIO graph: Reciprocal relationship from JNJ graph: Reciprocal relationship from HBIO graph: Reciprocal relationship from JNJ graph: Reciprocal relationship from HBIO gra… |
| IMNM | Immunome, Inc. | 72% | Reciprocal relationship from IMNM graph: Reciprocal relationship from JNJ graph: Reciprocal relationship from IMNM graph: m in accordance with the FDA’s good clinical practice, or GCP, requirements, … |
| IMVT | Immunovant, Inc. | 72% | Reciprocal relationship from IMVT graph: gulated, unapproved and off-label treatments. Even if a biosimilar product is less effective than our product candidates, a less effective biosimilar may be m… |
| IVF | INVO Fertility, Inc. | 72% | Reciprocal relationship from IVF graph: Reciprocal relationship from JNJ graph: Reciprocal relationship from IVF graph: ls for our product candidates may be larger than it anticipates, enrollment in … |
| JANX | Janux Therapeutics, Inc. | 72% | Reciprocal relationship from JANX graph: Reciprocal relationship from JNJ graph: Reciprocal relationship from JANX graph: ach master cell bank is or will be stored in two independent locations, and w… |
| KYMR | Kymera Therapeutics, Inc. | 72% | Reciprocal relationship from KYMR graph: hese manufacturers on a purchase order basis and do not have long-term supply arrangements in place. Should any of these manufacturers become unavailable to u… |
| KYTX | Kyverna Therapeutics, Inc. | 72% | Reciprocal relationship from KYTX graph: Reciprocal relationship from JNJ graph: Reciprocal relationship from KYTX graph: a have agreed, subject to certain exceptions, to indemnify each other against… |
| LEGN | Legend Biotech Corporation | 72% | Reciprocal relationship from LEGN graph: ct and product candidates have a limited window of stability following apheresis from a patient, we must establish and employ complex logistical operations, i… |
| LENZ | LENZ Therapeutics, Inc. | 72% | Reciprocal relationship from LENZ graph: Good Manufacturing Practices (“cGMP”) regulatory guidelines. A Drug Master File (“DMF”) is on file with the FDA for the API. Commercial supply agreements have… |
| LNSR | LENSAR, Inc. | 72% | Reciprocal relationship from LNSR graph: zation efforts will provide us with significant opportunity for future growth as we continue to penetrate existing and new markets. Our ALLY System currently … |
| LQDA | Liquidia Corporation | 72% | Reciprocal relationship from LQDA graph: -offs related to Sandoz’s inability to sell Treprostinil Injection, including in the event that Treprostinil Injection expires prior to sale. Currently, Trepr… |
| LTRN | Lantern Pharma Inc. | 72% | Reciprocal relationship from LTRN graph: the US, Australia, Canada, EU, China, and Japan. LP-300 Our portfolio directed to LP-300 consists of at least four families of owned patents. A more recent PC… |
| MDNC | Medinotec Inc. | 72% | Reciprocal relationship from MDNC graph: countries in which the Medinotec Group does business, including the US. These initiatives put increased emphasis on the delivery of more cost-effective medica… |
| MGNX | MacroGenics, Inc. | 72% | Reciprocal relationship from MGNX graph: Co., Ltd., Merck & Co., Inc., in collaboration with its partner, Daiichi and Pfizer Inc. These companies have significantly greater resources than we do. Furt… |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| JNJ-DEBT | Debt stack $55.0B | 90% | Market cache reports total debt of $55.0B. |
| JNJ-DEBT-6640 | Xbrl Convertible | 90% | xbrl convertible detail from xbrl 2023-01-01. |
| Holder | Name | Confidence | Evidence |
|---|---|---|---|
| JNJ-OWNER-MORGAN-STANLEY | Morgan Stanley | 95% | 13F/ownership overlay lists Morgan Stanley; shares held 48,231,667; ownership 2.00%; value $11.7B; as of 2025-09-30. |
| JNJ-OWNER-BLACKROCK-INC | Blackrock Inc. | 95% | 13F/ownership overlay lists Blackrock Inc.; shares held 208,781,159; ownership 8.67%; value $50.8B; as of 2025-12-31. |
| JNJ-OWNER-NORGES-BANK | NORGES BANK | 95% | 13F/ownership overlay lists NORGES BANK; shares held 33,459,884; ownership 1.39%; value $8.1B; as of 2025-12-31. |
| JNJ-OWNER-STATE-FARM-MUTUAL-AUTOMOBILE-INSURANCE-C | State Farm Mutual Automobile Insurance Co | 95% | 13F/ownership overlay lists State Farm Mutual Automobile Insurance Co; shares held 31,590,952; ownership 1.31%; value $7.7B; as of 2025-12-31. |
| JNJ-OWNER-NORTHERN-TRUST-CORPORATION | Northern Trust Corporation | 95% | 13F/ownership overlay lists Northern Trust Corporation; shares held 29,972,551; ownership 1.24%; value $7.3B; as of 2025-09-30. |
| JNJ-OWNER-BANK-OF-AMERICA-CORPORATION | Bank of America Corporation | 95% | 13F/ownership overlay lists Bank of America Corporation; shares held 28,419,787; ownership 1.18%; value $6.9B; as of 2025-09-30. |
| JNJ-OWNER-VANGUARD-GROUP-INC | Vanguard Group Inc | 95% | 13F/ownership overlay lists Vanguard Group Inc; shares held 240,349,660; ownership 9.98%; value $58.5B; as of 2025-12-31. |
| JNJ-OWNER-STATE-STREET-CORPORATION | State Street Corporation | 95% | 13F/ownership overlay lists State Street Corporation; shares held 132,206,061; ownership 5.49%; value $32.2B; as of 2025-09-30. |
| JNJ-OWNER-GEODE-CAPITAL-MANAGEMENT-LLC | Geode Capital Management, LLC | 95% | 13F/ownership overlay lists Geode Capital Management, LLC; shares held 57,953,747; ownership 2.41%; value $14.1B; as of 2025-12-31. |
| JNJ-OWNER-JPMORGAN-CHASE-CO | JPMORGAN CHASE & CO | 95% | 13F/ownership overlay lists JPMORGAN CHASE & CO; shares held 58,558,238; ownership 2.43%; value $14.3B; as of 2025-12-31. |
| JNJ-OWNER-JOHNSON-JOHNSON | JOHNSON & JOHNSON | 90% | 13F overlay lists JOHNSON & JOHNSON as top holder; 101 tracked holders. |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| CRBU | Caribou Biosciences, Inc. | 100.00 | 2 | |
| DAVA | Endava plc | 100.00 | 2 | |
| CRBP | Corbus Pharmaceuticals Holdings, Inc. | 100.00 | 2 | |
| CLYM | Climb Bio, Inc. | 100.00 | 2 | |
| AURX | Nuo Therapeutics, Inc. | 100.00 | 2 | |
| DAWN | Day One Biopharmaceuticals Inc | 100.00 | 2 | |
| CRARF | Crédit Agricole S.A. | 100.00 | 2 | |
| AUTL | Autolus Therapeutics plc | 100.00 | 2 | |
| AGM | Federal Agricultural Mortgage Corporation | 100.00 | 2 | |
| CTSH | Cognizant Technology Solutions Corporation | 100.00 | 2 | |
| CYCN | Cyclerion Therapeutics, Inc. | 100.00 | 1 | ['customer'] |
| BORAY | Bora Pharmaceuticals Co., Ltd. | 100.00 | 2 | |
| CVRX | CVRx, Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| BPTH | Bio-Path Holdings, Inc. | 100.00 | 2 | |
| BLNK | Blink Charging Co. | 100.00 | 1 | ['supplier'] |
| AXSM | Axsome Therapeutics, Inc. | 100.00 | 2 | |
| CTMX | CytomX Therapeutics, Inc. | 100.00 | 2 | |
| CTNM | Contineum Therapeutics, Inc. | 100.00 | 2 | |
| BSX | Boston Scientific Corporation | 100.00 | 2 | |
| DEO | Diageo plc | 100.00 | 2 |